Eczema Healthcare Use in Korea: A 270,008-Person National Claims Study

November 10, 2026

Research focus: large Korean national insurance claims study of 270,008 people with atopic dermatitis. This evidence review explains what the study measured, what its cost numbers can and cannot mean, and why economic association is not proof that a symptom, treatment or product caused the spending.

Key finding: Healthcare use differed by age, comorbidity and treatment pattern, demonstrating the scale of diagnosed eczema care in a national system. [1] Main limitation: Claims capture reimbursed encounters, not symptoms, over-the-counter care, unpaid work or disease control; coding and treatment indication can be misclassified.

Why the economic burden of eczema matters

Eczema can create costs far beyond a prescription receipt. Direct medical costs include clinician visits, tests, emergency care, hospital care and reimbursed medicines. Direct nonmedical and out-of-pocket costs can include moisturizers, bathing products, dressings, special clothing, transportation and childcare. Indirect costs include missed work, reduced productivity, school absence and unpaid caregiving. [2] [3]

Those categories should not be collapsed into one universal price tag. A claims database sees billed services but misses cash purchases and unpaid time. A household survey can capture those experiences but is vulnerable to recall and volunteer bias. A cost-of-illness study describes burden; it does not by itself show that a particular treatment would save money. [18] [19]

How this study was designed

This was large Korean national insurance claims study of 270,008 people with atopic dermatitis. The design sets the boundary of the conclusion. Claims studies are strong for large-scale reimbursed use but weak for symptoms and self-care. Surveys capture family experience but depend on memory. Matched cohorts can reduce measured differences, but unmeasured health, income and access factors may remain. [4] [5]

Measure	What it can show	What it cannot show alone
Paid claim	A reimbursed service or medicine was billed	That eczema caused every dollar
Out-of-pocket survey	What families remember paying	An audited national expenditure total
Work-productivity score	Reported absence or reduced performance	An employer-verified causal loss
Severity-cost association	Higher severity and higher cost occurred together	That severity alone caused cost or treatment caused severity
Country estimate	Burden in one price and reimbursement system	The same burden in every country or year

What the investigators found

Healthcare use differed by age, comorbidity and treatment pattern, demonstrating the scale of diagnosed eczema care in a national system. [6] The result applies to the participants, observation window, price year, health system, severity definition and cost categories used. It should not be converted into a guaranteed personal bill or a universal savings estimate. [7] [8]

Higher severity often travels with infection, sleep loss, comorbidity, specialist care and more treatment. That makes severity an important marker of burden but not a simple one-way cause. More care may reflect worse disease; treatment access may also change measured severity; and people without access may have low recorded cost despite high unmet need. [9] [10]

Direct costs, household costs and indirect costs are different

Direct medical cost estimates depend on whether investigators counted eczema-related claims, all-cause claims or both. All-cause totals may include asthma, food allergy, depression or unrelated care. Eczema-related coding can miss visits where eczema was not the primary code. Readers should look for the numerator, comparator and attribution rule before repeating a number. [11] [12]

Household spending can be invisible to insurers. Families may buy several moisturizers, cleansers, laundry products, clothing or bedding while searching for tolerable routines. Some purchases may help comfort; others may be ineffective or unnecessary. A high expense therefore documents burden, not product efficacy. [13] [14]

Indirect costs may include absence, presenteeism, time spent applying treatment, disrupted sleep and travel. Presenteeism is especially difficult to value because people may be at work or school while functioning below their usual level. Methods that multiply hours by wages are useful for comparison but are not precise household income statements. [15] [16]

Why country and year matter

A dollar, euro, pound, yen or won estimate belongs to a specific price year. Inflation, exchange rates, insurance design, deductibles, paid leave, pharmacy coverage and specialist access can change burden dramatically. Converting currencies without purchasing-power and price-year adjustment can create a misleading ranking. [17] [20]

New treatments can shift spending from visits or hospital care toward pharmacy cost, or the reverse. A study from an older treatment era remains useful historically but should not be presented as a current forecast. Likewise, national averages can conceal regional, racial, income and insurance inequities. [21] [2]

Children and caregivers

Pediatric burden belongs to the family system. Caregivers may miss work, lose sleep, arrange childcare, travel to appointments and spend time on bathing, dressings and medicine. School absence can affect learning and social participation, but an absence association does not prove eczema was the only reason. [6] [11]

Infants and young children need age-appropriate medical care. Families should not ration prescribed therapy, attempt elimination diets, or substitute unverified products because of cost without discussing safer alternatives with the child’s clinician. Food challenges, systemic medicines and treatment escalation require professional oversight. [18] [19]

Equity and access

Low recorded spending can mean low need, but it can also mean delayed care, underinsurance or inability to afford treatment. A fair interpretation considers both utilization and unmet need. Shared decision-making should include coverage, transportation, work schedules, language, health literacy and the practical time required for a regimen. [4] [8]

Clinicians can reduce avoidable burden by writing clear action plans, prioritizing evidence-based essentials, reviewing technique and adherence, prescribing affordable alternatives when appropriate, and identifying infection or uncontrolled inflammation early. These are care principles—not proof that any single strategy will reduce total cost for every family. [13] [17]

What this evidence cannot settle

Claims capture reimbursed encounters, not symptoms, over-the-counter care, unpaid work or disease control; coding and treatment indication can be misclassified. [undefined] [undefined] Observational cost research is especially vulnerable to confounding by indication: people who are sicker receive more intensive treatment and also incur higher costs, which can make treatment appear associated with cost even when severity drove both.

Industry sponsorship, survey recruitment, missing data, treatment-era changes and choice of statistical model can also influence results. Transparent reporting of absolute numbers, uncertainty and included cost categories is more informative than a single dramatic headline. [undefined] [undefined]

Questions patients and families can ask

Which parts of my regimen are medically essential?
Are lower-cost formulations, larger sizes or covered alternatives available?
Which warning signs require urgent care and which can be handled with an action plan?
Could technique or adherence be improved before adding products?
What assistance programs or insurance appeals are appropriate?
How should school or workplace accommodations be documented?
How will we measure disease control and whether a change is worthwhile?
Which expenses should be avoided because evidence is weak?

Where Dr. Arsy #003 fits—and where it does not

Dr. Arsy #003 was not the product studied in this research. Cost, utilization, productivity and treatment findings cannot be transferred to #003. #003 is a cosmetic moisturizer for dry, sensitive, eczema-prone skin. It is not claimed to treat, cure or prevent eczema, reduce healthcare spending, replace prescribed therapy or produce the economic outcomes reported here.

Readers considering routine cosmetic hydration can view the actual 4-oz Dr. Arsy Moisturizer #003. A moisturizer should be evaluated for its intended cosmetic role, tolerability and affordability—not as a promised medical or financial intervention.

Bottom line

This study adds useful evidence about who bears eczema-related costs and where those costs appear. The safest interpretation separates billed care from household spending, association from causation, and group averages from an individual family’s experience. [undefined] [undefined]

Related Dr. Arsy research articles

References

← Back to Doctor's Notes